Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
IKNA

IKNA - Ikena Oncology, Inc. Stock Price, Fair Value and News

$7.35+0.23 (+3.23%)
Market Closed

7/100

IKNA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

7/100

IKNA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$5.22

Target 3M

$5.88

Target 6M

$5.55

IKNA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

IKNA Price Action

Last 7 days

10.6%

Last 30 days

23.4%

Last 90 days

-9.7%

Trailing 12 Months

-58.8%

IKNA RSI Chart

IKNA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

IKNA Valuation

Market Cap

82.2M

Price/Earnings (Trailing)

-1.9

Price/Sales (Trailing)

12.91

EV/EBITDA

0.43

Price/Free Cashflow

-1.86

IKNA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$5.22

Target 3M

$5.88

Target 6M

$5.55

IKNA Fundamentals

IKNA Revenue

Revenue (TTM)

7.5M

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

IKNA Earnings

Earnings (TTM)

-43.3M

Earnings Growth (Yr)

-678.48%

Earnings Growth (Qtr)

-226.68%

IKNA Profitability

EBT Margin

-607.00%

Return on Equity

-30.93%

Return on Assets

-26.89%

Free Cashflow Yield

-53.64%

IKNA Investor Care

Shares Dilution (1Y)

508.81%

Diluted EPS (TTM)

-16.47

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20257.0M000
20246.5M05.0M3.5M
202317.5M19.2M14.0M8.0M
202230.9M27.7M30.4M15.6M
20219.4M9.9M10.8M31.0M
20200009.2M
Get all data in R, Python etc through our Historical Stock Data APIs

About Ikena Oncology, Inc.

IKNA
Ikena Oncology, Inc. operates as an oncology company that develops precision medicines to biomarker-defined patients with specific unmet needs in the United States. Its lead oncology product candidate is IK-930, a paralog selective inhibitor of the transcriptional enhanced associate domain, a transcription factor in the Hippo signaling pathway. It also develops IK-595, designed to trap MEK and RAF for inhibiting RAS signals than existing inhibitors; and IK-175, a monotherapy and in combination with nivolumab in patients with advanced or metastatic solid tumors, including urothelial carcinomas. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
 CEO
 WEBSITEhttps://ikenaoncology.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES59

Ikena Oncology, Inc. Frequently Asked Questions

IKNA is the stock ticker symbol of Ikena Oncology, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Tue Jan 27 2026, market cap of Ikena Oncology, Inc. is 82.19 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check IKNA's fair value in chart for subscribers.

The fair value guage provides a quick view whether IKNA is over valued or under valued. Whether Ikena Oncology, Inc. is cheap or expensive depends on the assumptions which impact Ikena Oncology, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IKNA.

As of Tue Jan 27 2026, IKNA's PE ratio (Price to Earnings) is -1.9 and Price to Sales (PS) ratio is 12.91. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IKNA PE ratio will change depending on the future growth rate expectations of investors.